Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria (HBV):~* HBsAg+ for at least 6 months prior to initiation of treatment.~* HBeAg+~* HBV titer \> 20000 copies/ml at start of treatment~* Treatment naïve~* HIV / hepatitis delta / HCV negative~* Compensated liver disease~* Ishak score ≤ 2~* Non cirrhotic~* No known active cytomegalovirus infection~* Willingness to utilize adequate contraception while being treated with REP 9AC (REP 2055) and for 6 months following the end of treatment~* Adequate venous access allowing weekly intravenous therapies and blood tests~Inclusion Criteria (HCV):~* HCV positive for at least 6 months prior to initiation of treatment~* Genotype 3~* HCV titer \>3log IU/ml at start of treatment~* Treatment naïve~* HIV / hepatitis delta / HBV negative~* Compensated liver disease~* Chronic alanine aminotransferase or aspartate aminotransferase elevation for 6 months prior to treatment~* Ishak score ≤ 2 (patients should only have mild fibrosis)~* Non cirrhotic~* No known active cytomegalovirus infection~* Willingness to utilize adequate contraception while being treated with REP 9AC (REP 2055) and for 6 months following the end of treatment~* Adequate venous access allowing weekly intravenous therapies and blood tests~Exclusion Criteria (HBV + HCV):~* Evidence of cardiovascular disease~* Autoimmune hepatitis~* Presence of Wilson's disease~* Presence of severe NAFLD~* Evidence of any other co-existent liver disease~* Anti-nuclear antibody): positive~* Anti-HIV 1: positive~* Evidence of liver cirrhosis~* A history of ascites, hepatic encephalopathy or variceal hemorrhage~* Body weight \> 100 kg~* Platelet count \< 75,000, polymorphonuclear cell count \< 1,500 or hematocrit \< 33%~* Alfa feto protein \> 100 ng/ml or the presence of a hepatic mass suggestive of hepatocellular carcinoma.~* Bilirubin \> 2.5 mg/dl~* Creatinine \> 1.5 mg/dl~* Platelets count \< 75,000 / cmm~* Serum albumin \< 35 mg/ml~* Poorly controlled diabetes mellitus~* Another serious medical disorder~* A serious psychiatric disorder~* Uncontrolled hypertension~* A history of alcohol abuse within the last year~* The use of illicit drugs within the past two years~* Inability to provide informed consent~* Positive pregnancy test~* Breastfeeding~* Inability or unwillingness to undergo a liver biopsy.~* Inability or unwillingness to provide weekly blood samples~* Poor venous access making weekly IV infusion too difficult

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- REP 2055 (Type: EXPERIMENTAL): Treatment with REP 2055

Based on this trial design, predict the completion outcome and termination type (if applicable).